DK1910384T3 - Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser - Google Patents

Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser

Info

Publication number
DK1910384T3
DK1910384T3 DK06789431.1T DK06789431T DK1910384T3 DK 1910384 T3 DK1910384 T3 DK 1910384T3 DK 06789431 T DK06789431 T DK 06789431T DK 1910384 T3 DK1910384 T3 DK 1910384T3
Authority
DK
Denmark
Prior art keywords
sirtuine
imidazo
modulating compounds
thiazol derivatives
thiazol
Prior art date
Application number
DK06789431.1T
Other languages
English (en)
Inventor
Joseph J Nunes
Jill Milne
Jean Bemis
Roger Xie
Chi B Vu
Pui Yee Ng
Jeremy S Disch
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1910384T3 publication Critical patent/DK1910384T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Surgery (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
DK06789431.1T 2005-08-04 2006-08-04 Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser DK1910384T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70561205P 2005-08-04 2005-08-04
US74178305P 2005-12-02 2005-12-02
US77937006P 2006-03-03 2006-03-03
US79227606P 2006-04-14 2006-04-14
PCT/US2006/030510 WO2007019344A1 (en) 2005-08-04 2006-08-04 Imidazo [2,1-b] thiayole derivatives as sirtuin modulating compounds

Publications (1)

Publication Number Publication Date
DK1910384T3 true DK1910384T3 (da) 2012-12-17

Family

ID=37074951

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06789431.1T DK1910384T3 (da) 2005-08-04 2006-08-04 Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser

Country Status (11)

Country Link
US (5) US20070037865A1 (da)
EP (7) EP1909910A1 (da)
JP (7) JP5203196B2 (da)
CN (1) CN103145738A (da)
AU (5) AU2006278396A1 (da)
CA (5) CA2618370A1 (da)
DK (1) DK1910384T3 (da)
ES (3) ES2431050T3 (da)
PL (1) PL1910384T3 (da)
PT (1) PT1910384E (da)
WO (5) WO2007019346A1 (da)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
WO2006073484A2 (en) * 2004-12-27 2006-07-13 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) * 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
KR101334511B1 (ko) 2004-12-30 2013-11-29 아스텍스 테라퓨틱스 리미티드 Ｃｄｋ, ｇｓｋ 및 오로라 키나아제의 활성을 조절하는피라졸 화합물
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
JP2008535790A (ja) * 2005-03-03 2008-09-04 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
EP1877054A2 (en) * 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1909910A1 (en) * 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007041641A1 (en) * 2005-10-03 2007-04-12 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
US8518980B2 (en) 2006-02-10 2013-08-27 Summit Corporation Plc Treatment of Duchenne muscular dystrophy
EP2049119A2 (en) 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
CA2676609A1 (en) * 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
JP2010523720A (ja) * 2007-04-12 2010-07-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ β−カテニン関連疾患の処置のための、サーチュインに基づいた方法および組成物
US9884031B2 (en) 2007-05-09 2018-02-06 The Trustees Of The University Of Pennsylvania Use of HDAC inhibitors for treatment of cardiac rhythm disorders
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TW200918542A (en) * 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US9370642B2 (en) 2007-06-29 2016-06-21 J.W. Medical Systems Ltd. Adjustable-length drug delivery balloon
AU2008278824A1 (en) * 2007-07-23 2009-01-29 Biomarin Iga Limited Compounds for treating Duchenne muscular dystrophy
TW200911237A (en) 2007-08-03 2009-03-16 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
KR20100065190A (ko) 2007-09-14 2010-06-15 닛토덴코 가부시키가이샤 약물 담체
WO2009039195A1 (en) * 2007-09-20 2009-03-26 Resveratrol Partners, Llc Resveratrol-containing compositions for modulating gene product concentration or activity
AU2008311827A1 (en) * 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
WO2009054994A2 (en) * 2007-10-23 2009-04-30 President And Fellows Of Harvard College Sirt-3 related methods and compositions for mimicking exercise
EP2216052A4 (en) * 2007-10-30 2012-11-21 Nihon Mediphysics Co Ltd USE OF A NEW COMPOUND WITH AFFINITY FOR AMYLOID AND METHOD FOR THE PRODUCTION THEREOF
CA2704336A1 (en) * 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
JP2011503066A (ja) * 2007-11-08 2011-01-27 サートリス ファーマシューティカルズ， インコーポレイテッド 可溶化チアゾロピリジン誘導体
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
CN101990433B (zh) * 2008-02-07 2014-11-05 马萨诸塞眼科耳科诊所 提高Atoh1表达的化合物
WO2009099643A1 (en) * 2008-02-07 2009-08-13 The J. David Gladstone Institutes Use of sirt1 activators or inhibitors to modulate an immune response
WO2009146030A1 (en) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
EP2257340A2 (en) * 2008-04-04 2010-12-08 BioMarin IGA Limited Compounds for treating muscular dystrophy
EA021938B1 (ru) * 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Хинолины и их аналоги в качестве модуляторов сиртуина
CN102088965B (zh) * 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
EP2300470A2 (en) * 2008-05-19 2011-03-30 Sepracor Inc. Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators
AU2009251324A1 (en) * 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
KR20110036602A (ko) * 2008-07-03 2011-04-07 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 벤즈이미다졸 및 관련 유사체
NZ601483A (en) 2008-08-04 2013-10-25 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010026124A1 (en) 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
DK2338059T3 (da) 2008-09-23 2015-06-15 Wista Lab Ltd Ligander for aggregerede tau-molekyler
AU2009295948B2 (en) 2008-09-29 2013-12-05 GlaxoSmithKline, LLC Quinazolinone, quinolone and related analogs as sirtuin modulators
AU2009314310A1 (en) * 2008-10-29 2010-05-20 Sirtris Pharmaceuticals, Inc. Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
GB0821307D0 (en) * 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2370086A2 (en) * 2008-12-01 2011-10-05 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
DK2376490T3 (da) * 2008-12-04 2013-04-15 Proximagen Ltd Imidazopyridinforbindelser
CA2746506A1 (en) 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
EA021424B1 (ru) 2008-12-19 2015-06-30 Сертрис Фармасьютикалз, Инк. Тиазолопиридиновые соединения, регулирующие сиртуин
WO2010090830A1 (en) * 2009-01-20 2010-08-12 Isis Pharmaceuticals, Inc. Modulation of sirt1 expression
WO2010088574A1 (en) * 2009-01-30 2010-08-05 Sirtris Pharmaceuticals, Inc. Azabenzimidazoles and related analogs as sirtuin modulators
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
AU2010236416A1 (en) * 2009-04-15 2011-11-03 Sanford-Burnham Medical Research Institute Naphthalene-based inhibitors of anti-apoptotic proteins
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
TWI482771B (zh) * 2009-05-04 2015-05-01 Du Pont 磺醯胺殺線蟲劑
BRPI1010600A2 (pt) 2009-05-15 2016-03-15 Novartis Ag aril piridina como inibidores de aldosterona sintase
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
CA2765030C (en) 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CN102573484B (zh) 2009-06-09 2015-07-01 加利福尼亚资本权益有限责任公司 苄基取代的三嗪衍生物及其治疗应用
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
BR112012010587A2 (pt) 2009-11-06 2015-09-29 David Gladstone Inst métodos e composições para modulação de níveis de tau.
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) * 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
CN102811620B (zh) 2010-01-25 2015-03-25 Chdi基金会股份有限公司 一些犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
CN102917700A (zh) * 2010-03-26 2013-02-06 国立大学法人北海道大学 神经退行性疾病治疗药物
EP2993236A1 (en) 2010-04-15 2016-03-09 Glaxosmithkline LLC Sirtuin activators and activation assays
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2563759B1 (en) * 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2011137089A1 (en) * 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
WO2011139387A1 (en) 2010-05-03 2011-11-10 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
EP2388255A1 (en) 2010-05-11 2011-11-23 Ikerchem, S.L. Polysubstituted benzofurans and medicinal applications thereof
US20120058088A1 (en) * 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
US20130158035A1 (en) * 2010-08-24 2013-06-20 Brigham Young University Antimetastatic compounds
CA2811025C (en) 2010-09-10 2018-07-17 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having ampk activating effect
KR20130051507A (ko) * 2010-09-15 2013-05-20 에프. 호프만-라 로슈 아게 아자벤조티아졸 화합물, 조성물 및 사용 방법
EP2640722B1 (en) 2010-11-19 2015-11-04 F.Hoffmann-La Roche Ag Pyrazolopyridines and their use as tyk2 inhibitors
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
DK2670404T3 (da) 2011-02-02 2018-11-19 Univ Princeton Sirtuinmodulatorer som virusproduktionsmodulatorer
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US9181231B2 (en) 2011-05-03 2015-11-10 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013049585A1 (en) * 2011-09-30 2013-04-04 Hengrui (Usa), Ltd. Arylsubstituted thiazolotriazoles and thiazoloimidazoles
RU2014120166A (ru) * 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
EP2790701A1 (en) * 2011-12-12 2014-10-22 SMB Innovation Novel heterocyclic compounds useful in sirtuin binding and modulation
WO2014007650A1 (en) * 2011-12-23 2014-01-09 Auckland Uniservices Limited Compounds and methods for selective imaging and/or ablation
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US20150133527A1 (en) * 2012-05-04 2015-05-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Regulation of cardiac sodium channels by sirt1 and sirt1 activators
PE20150194A1 (es) 2012-05-21 2015-02-08 Novartis Ag Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
EP2671885A1 (en) * 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
EP2682395A1 (en) 2012-07-04 2014-01-08 Laboratorios Del. Dr. Esteve, S.A. Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
ES2676422T3 (es) * 2012-07-04 2018-07-19 Zz Biotech Llc Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
WO2014012050A2 (en) * 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
WO2015042685A1 (en) * 2013-09-25 2015-04-02 Valorisation-Recherche Inhibitors of polynucleotide repeat-associated rna foci and uses thereof
SG11201503774PA (en) 2012-11-13 2015-06-29 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
CN103027912A (zh) * 2012-12-11 2013-04-10 南京医科大学附属南京儿童医院 N-[2-[3-(1-哌嗪基甲基)咪唑并[2,1-b]噻唑-6-基]苯基]-2-喹喔啉甲酰胺在制备防治高血压药物中的应用
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
WO2014187922A1 (en) * 2013-05-24 2014-11-27 Iomet Pharma Ltd. Slc2a transporter inhibitors
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
HK1224204A1 (en) * 2013-10-29 2017-08-18 Tokyo University Of Agriculture Frataxin enhancer
EP3791870A1 (en) 2013-12-02 2021-03-17 The Trustees of Columbia University in the City of New York Modulating ferroptosis and treating excitotoxic disorders
MY175865A (en) 2013-12-19 2020-07-14 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
CN106536535A (zh) 2014-06-02 2017-03-22 葛兰素史密斯克莱知识产权（第2 号）有限公司 结晶的β‑D‑烟酰胺核苷的制备和用途
BR112016028404A2 (pt) * 2014-06-05 2018-07-03 Bayer Cropscience Aktiengesellschaft compostos bicíclicos como pesticidas
WO2015186114A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
US10272070B2 (en) 2014-10-14 2019-04-30 The Board of Trustees of the Leland Stanford Junio r University Method for treating neurodegenerative diseases
LT3209655T (lt) 2014-10-24 2021-01-11 Landos Biopharma, Inc. Medicininiai preparatai į lantionino sintezę c panašaus baltymo 2 pagrindu
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
PL3328843T3 (pl) * 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
PT3331864T (pt) 2015-08-04 2022-01-18 Chong Kun Dang Pharmaceutical Corp Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
JP6937748B2 (ja) * 2015-10-08 2021-09-22 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 複素環で置換した二環式アゾール有害生物防除剤
CA3001666C (en) 2015-10-12 2021-03-30 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
WO2017096270A1 (en) * 2015-12-03 2017-06-08 The Regents Of The University Of California Methods for treating mitochondrial diseases
EP3390367B1 (en) 2015-12-15 2020-09-09 The Board of Trustees of the Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255B1 (en) 2016-01-20 2025-12-31 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2017152073A1 (en) 2016-03-04 2017-09-08 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels)
PT3426243T (pt) 2016-03-09 2021-08-19 Raze Therapeutics Inc Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
EP3426244B1 (en) 2016-03-09 2023-06-07 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3680241A1 (en) 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
KR102101234B1 (ko) * 2017-04-18 2020-04-16 부산대학교 산학협력단 신규 sirt 1 활성화제 및 이의 의학적 용도
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
CN107173817A (zh) * 2017-05-19 2017-09-19 广州弘宝元生物科技有限公司 sir2蛋白在制备抗氧化的食品或药品中的应用
KR102101235B1 (ko) * 2017-07-13 2020-04-16 부산대학교 산학협력단 신규 sirt 1 활성화제 및 이의 의학적 용도
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11612681B2 (en) * 2017-09-06 2023-03-28 The Research Foundation For The State University Of New York Compositions and devices for removal of endotoxins and cytokines from fluids
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
AU2018350980C1 (en) 2017-10-18 2024-12-12 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
US11730810B2 (en) 2017-11-14 2023-08-22 Children's Medical Center Corporation Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response
WO2019099564A1 (en) 2017-11-14 2019-05-23 Children's Medical Center Corporation Novel imidazopyrimidine compounds and uses thereof
WO2019108418A1 (en) 2017-11-30 2019-06-06 Landos Biopharma, Inc. Therapies with lanthionine c-like protein 2 ligands and cells prepared therewith
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
JP7526673B2 (ja) 2018-02-20 2024-08-01 インサイト・コーポレイション がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
KR102101236B1 (ko) * 2018-04-19 2020-04-16 부산대학교 산학협력단 신규 sirt 1 활성화제 및 이의 의학적 용도
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
MX2021001456A (es) 2018-08-06 2021-05-27 Univ Leland Stanford Junior 2-arilbenzimidazoles como activadores de ppargc1a para tratar enfermedades neurodegenerativas.
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN108774187A (zh) * 2018-08-14 2018-11-09 天津安浩生物科技有限公司 一种苯并噁唑衍生物其制备方法和应用
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
AU2019416589B2 (en) * 2018-12-29 2023-04-06 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound intermediate, preparation method therefor and application thereof
JP7536767B2 (ja) 2018-12-31 2024-08-20 バイオメア フュージョン，インコーポレイテッド メニン－ｍｌｌ相互作用の不可逆的阻害剤
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
MY207444A (en) 2019-05-31 2025-02-27 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
HUE072832T2 (hu) 2019-09-19 2025-12-28 Novo Nordisk Healthcare Ag Piruvát kináz R-t (PKR) aktiváló készítmények
WO2021070957A1 (ja) * 2019-10-09 2021-04-15 国立大学法人東北大学 ベンゼン縮合環化合物、およびそれを含有する医薬組成物
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN113748109B (zh) 2019-12-20 2023-07-21 朗多生物制药股份有限公司 羊毛硫氨酸c样蛋白2配体、用所述配体制备的细胞以及使用所述配体的疗法
EP4090424A4 (en) 2020-01-13 2024-02-21 The Feinstein Institutes for Medical Research TREATMENT OF BLEEDING AND BLEEDING DISORDERS BY HIGH-INTENSITY FOCUSED ULTRASONIC STIMULATION OF THE SPLEEN
MX2022008334A (es) 2020-01-17 2022-08-04 Daegu Gyeongbuk Medical Innovation Found Nuevo compuesto, metodo de preparacion del mismo y uso del mismo.
US20230096380A1 (en) * 2020-02-06 2023-03-30 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases and nerve damage, and methods for preparing compounds
FR3110398B1 (fr) * 2020-05-20 2022-06-03 Centre Nat Rech Scient Composés pour leur utilisation pour la réactivation du VIH dans des cellules latentes infectées par le VIH
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
EP4215526A4 (en) 2020-09-18 2024-10-16 Shanghai Pharmaceuticals Holding Co., Ltd. HETEROCYCLIC CARBONYL COMPOUND AND ITS USE
IT202000023281A1 (it) * 2020-10-02 2022-04-02 Univ Degli Studi Del Piemonte Orientale A Avogadro Inibitore o antagonista di sirt1 per uso nella prevenzione e/o trattamento di un tumore indotto da hpv
CN114380819B (zh) * 2020-10-22 2024-08-23 鲁南制药集团股份有限公司 一种唑吡坦中间体化合物
KR102694819B1 (ko) * 2021-01-29 2024-08-14 한국화학연구원 벤조티아졸 및 벤즈이미다졸 유도체, 약제학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
CN113321667B (zh) * 2021-05-26 2022-04-22 中国药科大学 氯诺昔康钠螯合物及其制备方法和应用
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
KR20240042098A (ko) * 2021-08-12 2024-04-01 클라리스 바이오, 인크. 연장 방출 크로마칼림 요법을 위한 조성물 및 방법
KR20240087693A (ko) 2021-08-20 2024-06-19 바이오메아 퓨전, 인크. 암 치료를 위한 비가역적 메닌-mll 억제제인 n-[4-[4-(4-모르폴리닐)-7h-피롤로[2,3-d]피리미딘-6-일]페닐]-4-[[3(r)-[(1-옥소-2-프로펜-1-일)아미노]-1-피페리디닐]메틸]-2-피리딘카르복스아미드의 결정질 형태
CN113769150B (zh) * 2021-10-22 2022-05-17 广东海洋大学 一种具有快速凝血作用的复合材料及其制备方法
EP4466064A4 (en) 2022-01-20 2026-01-14 Setpoint Medical Corp TREATMENT OF INFLAMMATORY DISORDERS
JP2025529523A (ja) * 2022-09-16 2025-09-04 延世大学校 産学協力団 ヘテロアリール誘導体化合物の抗ウィルス用途
US12012370B1 (en) * 2022-12-29 2024-06-18 Codagen Biosciences, Inc. Sirtuin modulating compounds and applications thereof
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
EP4656189A1 (en) 2023-02-01 2025-12-03 Benethera (Shaoxing) Biotechnology Co., Ltd. Compound and use thereof
AU2024218229A1 (en) * 2023-02-10 2025-08-07 Sirtsei Pharmaceuticals, Inc. Compositions and methods for treating anhedonia
WO2025221944A1 (en) * 2024-04-18 2025-10-23 Sirtsei Pharmaceuticals, Inc. Compositions and methods for treating joint and bone diseases

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164603A (en) * 1965-01-05 xnhcox
GB138286A (en) 1919-09-05 1920-02-05 Robert Bertram Grey Improvements in or relating to mixing apparatus
DE1108698B (de) 1959-09-03 1961-06-15 Hoechst Ag Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen
FR1439129A (fr) 1965-04-02 1966-05-20 Chimetron Nouveaux sulfonylbenzimidazoles
FR1476529A (fr) 1965-04-24 1967-04-14 Chimetron Sarl Nouveaux dérivés benzimidazole-sulfoniques et sulfamides correspondants
FR1450625A (fr) * 1965-06-18 1966-06-24 Chimetron Sarl Sulfonamidothiazolyl-2 benzimidazoles
US3503929A (en) * 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
US3517007A (en) * 1968-04-05 1970-06-23 American Home Prod 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds
US3928228A (en) * 1969-04-28 1975-12-23 Sterling Drug Inc 4,4{40 -Stilbenebis-pyridooxazoles and related optical brighteners and polymeric compositions brightened thereby
US3712888A (en) * 1970-12-14 1973-01-23 American Cyanamid Co Bis-pyridoxazole-stilbene derivatives for optical brightening
AR208500A1 (es) * 1972-06-14 1977-02-15 Merck & Co Inc Procedimiento para la preparacion de derivados de oxazolo(4,5-b)-piridinas
ZA735753B (en) 1972-09-14 1974-07-31 American Cyanamid Co Resolution of 6-substituted amino phenyl-2,3,5,6-tetrahydro(2,1-b)thiadiazoles
JPS5331880B2 (da) 1973-07-20 1978-09-05
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
PL96241B1 (pl) 1975-06-30 1977-12-31 Sposob wytwarzania 2-/2-podstawionych-4-tiazolilo/-benzimidazoli
US4018932A (en) 1975-11-03 1977-04-19 American Cyanamid Company Anthelmintic pour-on formulations for topical use on domestic and farm animals
JPS5929594B2 (ja) 1976-01-19 1984-07-21 ウェルファイド株式会社 アルコ−ル誘導体
JPS6040016B2 (ja) * 1977-08-31 1985-09-09 コニカ株式会社 マゼンタ色素画像の形成方法
US4471040A (en) * 1980-09-10 1984-09-11 Canon Kabushiki Kaisha Electrophotographic disazo photosensitive member
US4665079A (en) 1984-02-17 1987-05-12 Warner-Lambert Company Antibacterial agents
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4571396A (en) 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
DE3807084A1 (de) 1988-03-04 1989-09-14 Knoll Ag Neue benzimidazo(1,2-c)chinazoline, ihre herstellung und verwendung
JP2844079B2 (ja) 1988-05-23 1999-01-06 塩野義製薬株式会社 ピリドンカルボン酸系抗菌剤
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5063507A (en) 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
JPH04190232A (ja) * 1990-11-26 1992-07-08 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH04191736A (ja) * 1990-11-27 1992-07-10 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
EP0553777B1 (en) 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
DE4203932A1 (de) 1992-02-11 1993-08-12 Deutsche Aerospace Sende-/empfangsmodul
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
JPH06247969A (ja) 1992-12-28 1994-09-06 Takeda Chem Ind Ltd 縮合複素環化合物及びそれを含む農園芸用殺虫剤
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
WO1995001782A2 (en) 1993-07-09 1995-01-19 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
JPH07291976A (ja) * 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
JP3258531B2 (ja) * 1994-05-31 2002-02-18 三井化学株式会社 ベンズイミダゾール誘導体
US5852011A (en) * 1994-05-31 1998-12-22 Mitsui Chemicals, Inc. Benzimidazole derivatives
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
EP0688772B1 (en) 1994-06-16 1999-05-06 LG Chemical Limited Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
JP3223090B2 (ja) * 1994-12-27 2001-10-29 三井化学株式会社 フェニルベンズイミダゾール誘導体
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
WO1996025918A1 (en) 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AUPN449295A0 (en) 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5808087A (en) * 1995-11-29 1998-09-15 Mitsui Chemicals, Inc. Sulfonium salts of pyrrolylbenzimidazoles
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5939091A (en) 1997-05-20 1999-08-17 Warner Lambert Company Method for making fast-melt tablets
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
CN1299358A (zh) 1997-12-31 2001-06-13 新泽西州州立大学(拉特格斯) 杂环拓扑异构酶毒性剂
EP2138191A1 (en) 1998-01-05 2009-12-30 University Of Washington Enhanced transport using membrane disruptive agents
HUP0102981A3 (en) * 1998-03-31 2002-10-28 Shionogi & Co Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof
IL141396A0 (en) * 1998-08-20 2002-03-10 Agouron Pharma Non-peptide gnrh agents, methods and intermediates for their preparation
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US6653309B1 (en) * 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
AU778393B2 (en) * 1999-05-12 2004-12-02 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
GB2351081A (en) * 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
KR100718830B1 (ko) 1999-06-23 2007-05-17 사노피-아벤티스 도이칠란트 게엠베하 치환된 벤즈이미다졸 및 이의 제조방법
WO2001021615A1 (fr) 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
US20020049176A1 (en) 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1284260A4 (en) * 2000-05-22 2004-03-31 Takeda Chemical Industries Ltd TYROSIN PHOSPHATASE INHIBITORS
CA2412462A1 (en) * 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP2002161084A (ja) 2000-11-28 2002-06-04 Sumitomo Pharmaceut Co Ltd 複素環誘導体
US20040010033A1 (en) * 2001-02-20 2004-01-15 Pfizer Inc. Non-peptide GnRH agents, methods and intermediates for their preparation
WO2002066454A1 (fr) 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
ITMI20010528A1 (it) 2001-03-13 2002-09-13 Istituto Biochimico Pavese Pha Complessi di resveratrolo con fosfolipidi loro preparazione e composizioni farmaceutiche e cosmetiche
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
KR20030083016A (ko) 2001-03-28 2003-10-23 브리스톨-마이어스스퀴브컴파니 신규 타이로신 카이나제 억제제
WO2002101073A2 (en) * 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
DE60235470D1 (de) * 2001-06-26 2010-04-08 Pharmacopeia Inc N-heterocyclische inhibitoren der expression von tnf-alpha
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
NZ530580A (en) * 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2004043335A2 (en) * 2001-09-13 2004-05-27 Genesoft, Inc. Methods of treating infection by drug resistant bacteria
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
JP2005298333A (ja) 2001-11-15 2005-10-27 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
AU2002349477A1 (en) 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7375222B2 (en) * 2002-02-05 2008-05-20 Astellas Pharma Inc. 2,4,6-Triamino-1,3,5-triazine derivative
RU2004126671A (ru) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
US7144896B2 (en) * 2002-03-18 2006-12-05 Merck Frosst Canada Ltd. Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
BR0308537A (pt) * 2002-03-20 2005-02-09 Metabolex Inc Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP4239463B2 (ja) 2002-04-09 2009-03-18 大正製薬株式会社 ３−トリフルオロメチルアニリド誘導体
JP4224979B2 (ja) 2002-04-09 2009-02-18 大正製薬株式会社 インターロイキン１２抑制剤
MXPA04010172A (es) * 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
JP2003313176A (ja) 2002-04-24 2003-11-06 Sankyo Co Ltd アミノアゾール誘導体
EA008769B1 (ru) * 2002-06-05 2007-08-31 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения диабета
ATE452879T1 (de) * 2002-07-12 2010-01-15 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1542997B1 (en) * 2002-07-24 2012-02-29 Dermira (Canada), Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2004075614A (ja) 2002-08-20 2004-03-11 Sankyo Co Ltd クロメン誘導体を含有する医薬
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
EP1562605A4 (en) * 2002-10-08 2006-07-12 Massachusetts Inst Technology COMPOUNDS FOR MODULATING CHOLESTER INTRANSPORT
MXPA05003432A (es) * 2002-10-09 2005-07-05 Pfizer Prod Inc Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos.
AU2003299378A1 (en) 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2004035013A2 (en) 2002-10-21 2004-04-29 L'oreal Process for dissolving lipophilic compounds, and cosmetic composition
WO2004039318A2 (en) * 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
JP2006513159A (ja) 2002-11-01 2006-04-20 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体
US7691296B2 (en) 2002-11-25 2010-04-06 Amorepacific Corporation Method for stabilizing active components using polyol/polymer microcapsule, and cosmetic composition containing the microcapsule
AU2003302497A1 (en) * 2002-11-27 2004-06-23 Ph. D. Edward M. Eddy Glyceraldehyde 3-phosphate dehydrogenase-s(gapds), a glycolytic enzyme expressed only in male germ cells,is a target for male contraception
WO2004067480A2 (en) * 2003-01-25 2004-08-12 Oxford Glycosciences (Uk) Ltd Substituted phenylurea derivatives as hdac inhibitors
AU2004212490B2 (en) * 2003-02-10 2008-05-15 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
RS53118B (sr) * 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
MXPA05009245A (es) * 2003-03-11 2005-10-19 Pfizer Prod Inc Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf).
WO2004080481A1 (en) 2003-03-13 2004-09-23 Novo Nordisk A/S Novel nph insulin preparations
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
WO2004087121A2 (en) 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
DE602004016328D1 (de) * 2003-05-13 2008-10-16 Hoffmann La Roche 2-imidazo-benzothiazole als adenosin-rezeptor liganden
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
AU2004263148B2 (en) * 2003-08-06 2008-08-21 Vertex Pharmaceuticals, Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
GB2405793A (en) 2003-09-12 2005-03-16 4 Aza Bioscience Nv Pteridine derivatives for treating TNF-alpha related disorders
WO2005026165A1 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
AU2004274154A1 (en) * 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
CN1997642B (zh) 2003-09-22 2012-06-13 詹森药业有限公司 7-氨基亚烷基-杂环喹诺酮类和萘啶酮类
CA2539117A1 (en) * 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
WO2005049602A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
JP2005162855A (ja) 2003-12-02 2005-06-23 Konica Minolta Holdings Inc 着色組成物、インクジェット記録用インク、カラートナー、光記録媒体、感熱転写記録材料用インクシート、カラーフィルター、及び該インクジェット記録用インクを用いたインクジェット記録方法
CA2549660A1 (en) 2003-12-15 2005-06-30 Japan Tobacco Inc. Cyclopropane compounds and pharmaceutical use thereof
CA2545821C (en) 2003-12-22 2010-09-21 Basilea Pharmaceutica Ag Aroylfuranes and aroylthiophenes
AU2005207029B2 (en) 2004-01-20 2011-09-01 Brigham Young University Novel sirtuin activating compounds and methods for making the same
US7310404B2 (en) * 2004-03-24 2007-12-18 Canon Kabushiki Kaisha Radiation CT radiographing device, radiation CT radiographing system, and radiation CT radiographing method using the same
CA2563743A1 (en) 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
CN101891680B (zh) * 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
US7517076B2 (en) * 2004-06-30 2009-04-14 Eastman Kodak Company Phase-change ink jet printing with electrostatic transfer
RU2007109073A (ru) * 2004-08-13 2008-09-20 Дженентек, Инк. (Us) Ингибиторы для атф-зависимого фермента на основе тиазола
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
WO2006070198A1 (en) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
JP2008535790A (ja) * 2005-03-03 2008-09-04 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
GB0508463D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
SG159561A1 (en) * 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
EP1909910A1 (en) 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
TW200918542A (en) * 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TWI331918B (en) * 2007-10-31 2010-10-21 Univ Kaohsiung Medical Imino-indeno[1,2-c]quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
EP1910362B1 (en) 2012-10-17
CA2618368A1 (en) 2007-02-15
US20120022254A1 (en) 2012-01-26
ES2431050T3 (es) 2013-11-22
US20090099170A1 (en) 2009-04-16
AU2006278505B2 (en) 2013-01-17
WO2007019345A1 (en) 2007-02-15
WO2007019346A1 (en) 2007-02-15
JP2012214480A (ja) 2012-11-08
PT1910384E (pt) 2013-01-23
AU2006278504A1 (en) 2007-02-15
AU2006278505A1 (en) 2007-02-15
PL1910384T3 (pl) 2013-03-29
AU2006278397A1 (en) 2007-02-15
CA2618360C (en) 2015-06-09
JP2009503114A (ja) 2009-01-29
JP5203193B2 (ja) 2013-06-05
JP5203195B2 (ja) 2013-06-05
CA2618360A1 (en) 2007-02-15
JP5203196B2 (ja) 2013-06-05
AU2006278396A1 (en) 2007-02-15
CA2617532A1 (en) 2007-02-15
AU2006278503A1 (en) 2007-02-15
US7345178B2 (en) 2008-03-18
US20070043050A1 (en) 2007-02-22
US20120197013A1 (en) 2012-08-02
EP1910380A1 (en) 2008-04-16
JP2009503117A (ja) 2009-01-29
CA2617557A1 (en) 2007-02-15
EP1910384B1 (en) 2012-10-10
US8163908B2 (en) 2012-04-24
EP2388263A1 (en) 2011-11-23
ES2396913T3 (es) 2013-03-01
EP2468752A1 (en) 2012-06-27
EP1910384A1 (en) 2008-04-16
JP5203194B2 (ja) 2013-06-05
AU2006278503B2 (en) 2013-01-17
JP2012211149A (ja) 2012-11-01
CA2618370A1 (en) 2007-02-15
WO2007019417A1 (en) 2007-02-15
AU2006278397B2 (en) 2013-01-17
EP1910385A1 (en) 2008-04-16
JP2009503113A (ja) 2009-01-29
EP1910362A1 (en) 2008-04-16
EP1909910A1 (en) 2008-04-16
EP1910385B1 (en) 2013-07-24
WO2007019344A1 (en) 2007-02-15
WO2007019416A1 (en) 2007-02-15
JP2009503112A (ja) 2009-01-29
US20070037865A1 (en) 2007-02-15
EP1910362B9 (en) 2013-02-20
US8044198B2 (en) 2011-10-25
AU2006278504B2 (en) 2013-01-17
WO2007019344A8 (en) 2010-08-12
JP2009508811A (ja) 2009-03-05
ES2397275T3 (es) 2013-03-05
CN103145738A (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
PL1910384T3 (pl) Pochodne imidazo[2,1-b]tiazolu jako związki modulujące sirtuinę
DK1902037T3 (da) 2,4-diamino-pyrimidiner som auroainhibitorer
DK2057154T3 (da) PYRIDO-(2,3-B)pyrazinderivater, der er anvendelige som herbicidale forbindelser
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
DK1904494T3 (da) Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
NL1031532A1 (nl) Nieuwe verbindingen van aminosulfonylderivaten.
DK1863787T3 (da) Hydrogeneret benzo[c]thiophenderivater som immunmodulatorer
DOP2007000080A (es) Piridin [3,4-b] pirazinonas
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
DK1578750T3 (da) Kationiske porphyrinderivater som antibakterielle midler
DK1954697T3 (da) Peri-kondenserede tricykliske forbindelser, der er anvendelige som antibakterielle midler
MA28554B1 (fr) Dérivés de morpholine
DK2069310T3 (da) Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
DK1901743T3 (da) Quinolinderivater som antibakterielle midler
DK1912648T3 (da) Quinolinderivater som antibakterielle midler
NL1031335A1 (nl) Gesubstitueerde N-sulfonylaminofenylethyl-2-fenoxyaceetamideverbindingen.
DE602006008072D1 (de) Elastomerverbindung
DK2044101T3 (da) Aminothiazolderivater samt deres anvendelser som antibakterielle midler
GB0523653D0 (en) Organic compounds
ZA200800213B (en) Benzimidazole derivatives as 5-HT6, 5-HT24
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE468844T1 (de) Stabilisierte gefriergetrocknete formulierung für cephalosporinderivate